Concord Biotech Limited · NSE: CONCORDBIO · BSE: 543960

Concord Biotech

Quarterly results as filed with BSE. Latest: Q1 FY27 (Apr–Jun 2026), filed 31 Jul 2026.

Q1 FY27 · Consolidated

Revenue
257.49₹ Cr
+26.2% vs year ago
Net profit
57.70₹ Cr
+31.0% vs year ago
EPS, basic
5.52₹
+31.1% vs year ago
Net margin
22.4%
+0.8 pts vs year ago
Revenue₹ crore · consolidated · last 12 quarters
Q2 FY24: ₹262.35 CrQ3 FY24: ₹240.80 CrQ4 FY24: ₹318.97 CrQ1 FY25: ₹215.80 CrQ2 FY25: ₹310.18 CrQ3 FY25: ₹244.22 CrQ4 FY25: ₹429.88 CrQ1 FY26: ₹203.99 CrQ2 FY26: ₹247.06 CrQ3 FY26: ₹277.77 CrQ4 FY26: ₹326.08 CrQ1 FY27: ₹257.49 CrQ3 ’24Q1 ’25Q3 ’25Q1 ’26Q3 ’26Q1 ’27
Net profit₹ crore · consolidated · last 12 quarters
Q2 FY24: ₹81.02 CrQ3 FY24: ₹77.57 CrQ4 FY24: ₹95.02 CrQ1 FY25: ₹59.59 CrQ2 FY25: ₹95.74 CrQ3 FY25: ₹75.92 CrQ4 FY25: ₹140.39 CrQ1 FY26: ₹44.06 CrQ2 FY26: ₹63.06 CrQ3 FY26: ₹63.64 CrQ4 FY26: ₹88.47 CrQ1 FY27: ₹57.70 CrQ3 ’24Q1 ’25Q3 ’25Q1 ’26Q3 ’26Q1 ’27

Quarter by quarter

Consolidated · ₹ crore
QuarterRevenueYoYNet profitYoYEPS (₹)Filed
Q1 FY27Apr–Jun 2026257.49+26.2%57.70+31.0%5.5231 Jul 2026
Q4 FY26Jan–Mar 2026326.08−24.1%88.47−37.0%8.4629 May 2026
Q3 FY26Oct–Dec 2025277.77+13.7%63.64−16.2%6.0811 Feb 2026
Q2 FY26Jul–Sep 2025247.06−20.4%63.06−34.1%6.0313 Nov 2025
Q1 FY26Apr–Jun 2025203.99−5.5%44.06−26.1%4.2108 Aug 2025
Q4 FY25Jan–Mar 2025429.88+34.8%140.39+47.8%13.4229 May 2025
Q3 FY25Oct–Dec 2024244.22+1.4%75.92−2.1%7.2614 Feb 2025
Q2 FY25Jul–Sep 2024310.18+18.2%95.74+18.2%9.1512 Nov 2024
Q1 FY25Apr–Jun 2024215.80+10.8%59.59+9.4%5.7012 Aug 2024
Q4 FY24Jan–Mar 2024318.97—95.02—9.0830 May 2024
Q3 FY24Oct–Dec 2023240.80—77.57—7.4120 Feb 2024
Q2 FY24Jul–Sep 2023262.35—81.02—7.7422 Nov 2023
Q1 FY24Apr–Jun 2023194.83—54.49—5.2106 Sep 2023
Standalone results
Standalone · ₹ crore
QuarterRevenueYoYNet profitYoYEPS (₹)Filed
Q1 FY27Apr–Jun 2026260.52+27.7%61.19+43.8%5.8531 Jul 2026
Q4 FY26Jan–Mar 2026325.89−24.2%90.02−36.6%8.6029 May 2026
Q3 FY26Oct–Dec 2025278.13+13.9%67.78−8.5%6.4811 Feb 2026
Q2 FY26Jul–Sep 2025247.06−20.4%62.90−36.3%6.0113 Nov 2025
Q1 FY26Apr–Jun 2025203.99−5.5%42.57−26.9%4.0708 Aug 2025
Q4 FY25Jan–Mar 2025429.88+34.8%141.94+46.0%13.5729 May 2025
Q3 FY25Oct–Dec 2024244.22+1.4%74.09−0.6%7.0814 Feb 2025
Q2 FY25Jul–Sep 2024310.18+18.2%98.70+16.8%9.4312 Nov 2024
Q1 FY25Apr–Jun 2024215.80+10.8%58.24+20.2%5.5712 Aug 2024
Q4 FY24Jan–Mar 2024318.97—97.21—9.2930 May 2024
Q3 FY24Oct–Dec 2023240.80—74.55—7.1320 Feb 2024
Q2 FY24Jul–Sep 2023262.35—84.49—8.0822 Nov 2023
Q1 FY24Apr–Jun 2023194.83—48.47—4.6306 Sep 2023

26 filings on record for this company.